Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noradrenaline vs. Terlipressin for Hepatorenal Syndrome in ACLF
NCT02573727Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Oct 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of norepinephrine in hepatorenal syndrome (HRS) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Response to treatment at 14 days. Started Oct 2015; status: completed.
02
Drugs
norepinephrine
03
Conditions
hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on NCT02573727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573727.